1	SARS-CoV-2 Detection in the Nasopharyngeal Swabs and Saliva of College
2	Students using RT-qPCR and RT-LAMP
3	
4	Authors:
5	D. A. Bikos ^{a,b} , C. Hwang ^b , K. A. Brileva ^b , A. Parker ^{b,d} , E. K. Loveday ^{a,b} , M. Rodriguez ^c , I. Thornton ^{e,b} , T. LeFevre ^{a,b} , J. N
6	Wilking ^{a,b} , M. Dills, S. T. Walk ^c , A. K. Adams ^f , R. K. Plowright ^c , A. B. Hoegh ^d , J. R. Carter ^g , J. Morrow ^b , M. P. Taylor ^c ,
7	D. E. Keil ^c , M. W. Fields ^{b,c*} , and C. B. Chang ^{a,b*}
8	
9	Affiliations:
10 11	^a Department of Chemical & Biological Engineering, Montana State University, Bozeman, MT 59717, United States ^b Center for Biofilm Engineering, Montana State University, Bozeman, MT 59717, United States
12	^c Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, United States
13	^d Department of Mathematical Sciences, Montana State University, Bozeman, MT 59717, United States
14	^e Department of Mechanical & Industrial Engineering, Montana State University, Bozeman, MT 59717, United
15	States
16	^f Center for American Indian and Rural Health Equity (CAIRHE), Montana State University, Bozeman, MT 59717,
17	United States
18 10	^g Health & Human Development, Montana State University, Bozeman, MT 59717, United States
20	*Co-corresponding authors:
21	Connie B. Chang
22	Department of Chemical and Biological Engineering
23	Center for Biofilm Engineering
24	Montana State University
25	
26	Matthew W. Fields
27	Department of Microbiology and Immunology
28	Center for Biofilm Engineering
29	Montana State University
3U 21	Abotroot
o⊥ oo	ADDITACI
5∠ 33	Background

Diagnostic testing can identify outbreaks and inform preventive strategies for slowing the spread of SARS-CoV-2, the
 virus that causes Covid-19. The "gold standard" method for detection of SARS-CoV-2 is reverse transcription
 quantitative polymerase chain reaction (RT-qPCR) performed on samples collected using nasopharyngeal (NP) swabs.
 While NP RT-qPCR achieves high sensitivity, it requires trained personnel to administer and suffers from lengthy time to-result. Instead, rapid saliva-based reverse transcription loop-mediated amplification (RT-LAMP) screening methods

39 may offer advantages in sample collection and speed.

40 Methods

Regardless of symptomatic presentation, a total of 233 individuals were tested for SARS-CoV-2 using NP RT-qPCR,
 alongside saliva-based RT-qPCR (SalivirDetect) and RT-LAMP (SLAMP), a simple and rapid fluorometric RT-LAMP

43 assay performed directly on heat-inactivated saliva without any additional treatments or RNA extraction. SLAMP is

44 conducted in triplicate and takes 45 min. Samples found negative using both saliva-based methods but positive under

45 CDC NP RT-qPCR above the saliva method LoD were excluded from evaluation, suggesting significant differences in

46 viral titer between sampling sites. Individuals who consumed potential inhibitors in the form of food, drink, and oral 47 health products within 30 min of sampling were identified using a self-reported guestionnaire.

48 Results

49 Of the 233 NP RT-qPCR tests, 58 were positive and 175 were negative. Comparatively, SLAMP resulted in 95% sensitivity and 98% specificity and SalivirDetect 97% sensitivity and 98% specificity. Prior consumption had no measurable effect on test outcomes, except for drinking, which lowered Ct values in saliva.

52 Conclusions

53 SLAMP requires less technician and instrument time than CDC-approved NP RT-gPCR and demonstrates that saliva-

54 based RT-LAMP can enable frequent and rapid identification of pre-symptomatic and asymptomatic SARS-CoV-2

55 infections with high sensitivity and specificity.

56 Introduction

The SARS-CoV-2 virus¹ emerged in late 2019, rapidly developing into a worldwide pandemic still 57 posing a persistent threat to public health, economics, and quality of life. While real-world vaccine 58 efficacy continues to be evaluated², uncertainties over variant escape³, vaccine availability⁴, and 59 duration of immunity⁵ suggest that testing will continue to play an indispensable role in managing 60 61 the disease into the future. Viral spread can be controlled by deploying diagnostic tests that rapidly identify infected individuals for guarantine and contact tracing. Rapid and frequent SARS-CoV-2 62 63 testing is needed to identify new outbreaks as the world struggles to lift lockdowns⁶ and reopen schools for in-person instruction in Fall 2021⁷. 64

65

The "gold standard" method for detecting SARS-CoV-2 has been reverse transcription quantitative polymerase chain reaction (RT-qPCR) performed on samples collected using nasopharyngeal (NP) swabs⁸. However, RT-qPCR testing requires significant reagent consumption, specialized equipment, trained operators, and several hours to perform. Collection of NP swab samples is invasive and must be performed by trained medical personnel. Performing surveillance at scale calls for innovative testing strategies that are inexpensive, minimize reagent consumption, decrease assay time-to-result, and avoid restrictions in available personnel^{9,10}.

73

74 One such alternative to RT-qPCR is reverse transcriptase loop-mediated isothermal amplification 75 (RT-LAMP), an isothermal technique for the amplification of RNA¹¹. RT-LAMP simplifies SARS-CoV-2 testing by eliminating the long assay times and technical barriers such as the electronically 76 77 controlled thermal cycling at high temperatures required by PCR-based methods¹²⁻¹⁷. RT-LAMP 78 is substantially faster than RT-qPCR, and when performed on saliva samples¹⁸, eliminates the need for specialized swabs and operators while assuaging the public reluctance to testing, largely 79 80 brought on by invasive NP swabs¹⁹. The RT-LAMP assay is usually completed within 45 min to confirm a negative, while some exceptionally high viral loads become detectable at $\approx 10 \text{ min}^{20}$. 81 82

Here, we report the findings of a multi-day pilot study to evaluate saliva-based SARS-CoV-2 83 84 detection using RT-qPCR and RT-LAMP methods compared alongside to Centers for Disease 85 Control and Prevention (CDC)-approved NP RT-gPCR testing at Montana State University (MSU) during mid-November 2020, a time when Covid-19 cases reached county-wide highs (Figure S1). 86 87 We present the results of SLAMP, a rapid fluorometric RT-LAMP assay performed directly on saliva without chemical extraction steps. Additionally, we compare SLAMP to SalivirDetect²¹, a 88 direct saliva-to-RT-qPCR assay and both saliva tests are compared to CDC-approved RT-qPCR 89 90 performed on samples swabbed from the nasopharynx. Each participant was provided a self-91 reported survey identifying samples collected within 30 min of consuming food, drink, or oral 92 hygiene products to determine the extent to which saliva test results might be affected. 93

94 <u>Methods</u>

9596 Participants

Samples were collected from 233 participants who visited the on-campus CDC-approved RT qPCR testing site provided for persons exhibiting Covid-19 symptoms or who suspected recent
 contact with SARS-CoV-2-positive individuals. We directly compared samples from two sources
 on the body of each participant, NP swabs, tested using CDC-approved RT-qPCR, and saliva,
 tested using SLAMP and SalivirDetect. All individuals tested signed a consent form before
 participating in this study (Supplementary Information – Consent Form).

- 103
- 104
- 105
- 106

107 Self-Reported Questionnaire

Participants were provided with a self-reported questionnaire (Supplementary Information -Questionnaire) that collected demographic information including age, gender, race, and ethnicity. Additionally, subjects were asked to confirm whether they were currently symptomatic or asymptomatic and whether they had recent contact with infected individuals. Finally, subjects were asked to disclose if they had, in the last 30 min, consumed food or liquid, used mouthwash, gum or lozongos, smoked vaporized or chowed tobacco, or brushed their tooth

- gum or lozenges, smoked, vaporized or chewed tobacco, or brushed their teeth.
- 114

115 Sample Collection

All sampling occurred at an outdoor parking lot in drive-through format while participants remained inside automobiles as an additional precaution against viral transmission. Individuals who expressed interest in participating in our pilot study were administered NP swabs by trained staff before donating an additional saliva sample as outlined by the university IRB (Supplementary Information – IRB).

121

122 Viral Inactivation - NP Swab

123 NP swabs were heat-inactivated by diluting collection buffer 1:2 with molecular biology grade H_2O 124 (50 µL buffer: 50 µL H_2O) and assigned a location on a 96-well PCR plate. Plates were covered 125 with sealing foil and heated to 95 °C for 5 min in a standard thermocycler before being cooled to 126 4 °C until ready to test.

126 127

128 Viral Inactivation - Saliva

129 In the case of saliva collection, participants were given a 3D-printed accessory caddy (Supplementary Methods, Figure S2) containing a 30-mL polypropylene medicine cup (MedPride 130 131 97205), a generic 1-mL transfer pipet, and a screw cap tube (VWR 16466-040). Saliva was 132 expressed into the medicine cup (Figure S3i) before using the pipet to transfer ≈1.0 mL into the 133 screw-cap tube (Figure S3ii). Tubes were indexed with heat- and water-resistant adhesive labels 134 (Electronic Imaging Materials, Inc. 667) prepared via barcode printer (TSC MB340T). Samples were inactivated using a heat block (Labnet AccuBlock) set to 95 °C for 15 min (Figure S3iii) 135 simultaneously during which time ribonucleases were denatured and virions lysed. While not 136 strictly necessary, samples were removed from heat treatment and left at room temperature for 137 20 min to allow debris in the saliva to settle for easier pipetting. Barcodes were entered into 138 139 records using a handheld scanner (Motorola Symbol LS2208-SR20007R-NA).

140

141 CDC-approved RT-qPCR from NP Swab

142 Next, 10 uL of diluted, heat-inactivated²² sample material was mixed with 15 µL of each 1-step PCR master mix consisting of: 1.) 1.5 µL each N1 and N2 primer probe set, 5 µL Quantabio 143 Ultraplex 1-Step Toughmix (4×), and 7 μ L H₂O per reaction; 2.) 1.5 μ L human RNase P reaction 144 primer probe mix, 5 μ L Quantabio Ultraplex 1-Step Toughmix (4×), and 8.5 μ L H₂O per reaction. 145 Real-time PCR thermocycling was performed per CDC guidelines²³. Each sample was screened 146 in a combined N1, N2 reaction with an internal control human RNase P reaction (Supplementary 147 Methods). Samples with no detectable fluorescence for either assay and those with SARS-CoV-148 2 target fluorescence between 39.5 and 45 cycle thresholds (Ct) were re-tested using a validated 149 150 RNA purification kit (Promega Maxwell RSC Viral Total Nucleic Acid Multi-Pack Kit, ASB1330). RNA-purified samples were assayed under the same conditions, but with 5 µL of purified sample 151 152 added to each reaction for 20 µL total reaction volume. No replicates were performed. 153

154 SalivirDetect - RT-qPCR in saliva

SLAMP was compared to the saliva-based RT-qPCR assay SalivirDetect with FDA Emergency Use Authorization (EUA) application number EUA202615, submitted August 25, 2020 and

157 developed by Drs. Phillip Buckhaults and Carolyn Banister (University of South Carolina).

158 SalivirDetect, like SLAMP, uses heating at 95 °C to process saliva without inactivation buffers or additives. SalivirDetect was conducted in the InHealth Life Sciences CLIA/CAP laboratory led by 159 160 Dr. Deborah Keil (MSU). Briefly, ≈5 mL of saliva was collected in a 50-mL centrifuge tube. The tube was placed in a 95 °C oven (Fisherbrand Isotemp General Purpose Heating and Drving 161 Oven) for 45 min, then allowed to sit at room temperature to cool. Two 5-uL aliguots of the saliva 162 were transferred to two wells in a 96-well plate containing Luna Kit RT-qPCR reagents (E3600, 163 New England Biolabs), one well containing N1 primers and the second well containing human 164 RNase P primers from the United States CDC Real-Time Reverse Transcription PCR Panel for 165 SARS-CoV-2 detection (Supplementary Methods). Samples were run on a CFX Opus 96 Real-166 Time qPCR instrument (Bio-Rad, cat no. 12011319). Only a single test per sample was performed 167 with no replicates. 168

169

170 SLAMP - RT-LAMP in saliva

171 RT-LAMP reactions were set up as described by protocol E1700 (New England Biolabs) at 25 μL final reaction volume with the following modified formulation: 12.5 µL WarmStart 2X Master Mix 172 (E1700L, New England Biolabs) 0.175 μL of dUTP (N0459S, New England Biolabs), 0.5 μL of 173 UDG (M0372L, New England Biolabs), 2.5 µL of duplex NE primer mix (Supplementary Methods), 174 0.5 μL of 25-μM SYTO-9 (S34854, Invitrogen), 0.25 μL of 25-μL ROX reference dye (61110, 175 Lumiprobe), 2.5 µL of 400-mM molecular biology grade guanidine HCI (GuHCI) (J65661, Alfa 176 Aesar), 1.075 µL of nuclease-free water (B1500L, New England Biolabs), and 5 µL of heat-177 178 inactivated saliva sample. Controls were run on each 96-well plate, including SARS-CoV-2negative heat-inactivated saliva as a no-template control (NTC), human beta-actin (ACTB) as a 179 positive internal control, and three positive test controls of 5×10^4 , 5×10^2 , and 5×10^0 copies/ μ L 180 synthetic SARS-CoV-2 RNA (NIST, RGTM 10169 Fragment 1) (Supplementary Methods). 181 Positive test control dilutions were made using heat-inactivated SARS-CoV-2-negative saliva. All 182 183 SLAMP reactions were prepared in 96-well qPCR plates (Applied Biosystems, 4483485) sealed using an ALPS 50V manual heat sealer (Thermo Scientific) with Clear Seal Diamond films (AB-184 0812, Thermo Scientific). Reactions were performed at 65 °C (1.6 °C/s ramp) on a QuantStudio 185 3 Real-Time PCR System (Applied Biosystems) (Figure S3iv) for 45 min. Fluorescence 186 measurements for SYTO-9 and ROX channels were recorded every 1 min. SARS-CoV-2 may be 187 188 present in highly variable amounts within the nasopharynx and the saliva²⁴. To avoid invalid test samples where RNA was present only in the NP swab, only NP RT-qPCR-positive samples that 189 also tested positive under at least one of the two saliva methods were included in this study. Any 190 191 time-to-positive Tp > 40 min was considered negative. See Supplementary Methods for reaction 192 curve-fitting procedure and SLAMP formulation optimization. Each saliva sample was run in 193 triplicate.

194

195 Statistical Analysis

196 Statistical bootstrapping²⁵ methods can predict how the normally triplicate SLAMP sensitivity and 197 specificity may change when performed only in duplicates or single tests. Using our (triplicate, 45 198 min) SLAMP test results, 1,000 random bootstrap samples were used to predict sensitivity with 199 respect to CDC-approved NP RT-qPCR at 95% confidence intervals when only 1 or 2 SLAMP 200 reactions are performed per sample. In addition, we model the outcomes of SLAMP testing under hypothetical disease prevalence scenarios. Based upon the experimental sensitivity of SLAMP in 201 202 triplicate and the bootstrap-predicted sensitivities of duplicate and single SLAMP tests, we 203 determine the total number of detectable positive individuals based on a daily testing capacity of 204 six 384-well plates, reserving 10 wells for controls when performed in triplicate, duplicate, or single 205 tests. Specificity is assumed to remain constant.

206

All t-tests are reported as p values. Pearson correlation coefficients are reported as r values.

208

209 **Results**

210

211 Comparing testing methods: SLAMP, SalivirDetect, and NP RT-qPCR.

We compare samples from two matrices, NP swab and saliva, across three different testing methods, SLAMP, SalivirDetect, and the "gold standard" CDC-approved NP RT-qPCR, the latter performed using NP swab while saliva, shown to provide sufficient viral RNA for detection^{26,27}, was used for both SLAMP and SalivirDetect. Both SalivirDetect and CDC-approved NP RT-qPCR are PCR-based while SLAMP uses isothermal LAMP amplification. SLAMP was performed in triplicate while SalivirDetect and NP RT-qPCR tests were performed only once (Figure 1).

218



219 220

221

222 **Demographics**

Participant ages ranged from 17 to 63 with a median age of 20. Males made up 47% and females 53%. Participants were comprised of 94% white and 6% other races including Asian and mixedrace individuals of American Indian, Alaskan Native, Native Hawaiian or Pacific Islander, and African American descent. Ethnically, 9 individuals self-reported as Hispanic or Latino, 207 as not Hispanic or Latino, and 17 chose not to respond (Table 1).

228

229 Clinical presentation

Participants self-reported their illness presentation as either symptomatic or asymptomatic and indicated whether they had knowledge of recent exposure to a confirmed Covid-19-positive individual. A majority 74% of study participants self-reported as symptomatic among whom 46% indicated knowledge of recent exposure. Among the 29% asymptomatic, 6% were unaware of exposure, the remaining 94% sought testing after learning of SARS-CoV-2 exposure (Table 1).

236

237 Potential saliva contamination

238 Testing was conducted on a first come, first served basis without appointments. Therefore, 239 instructions to abstain from food, drink, or oral hygiene products before donating saliva could not be provided to participants ahead of time. To determine the extent to which saliva may have been 240 affected, the questionnaire asked participants whether they had eaten food or consumed drinks 241 242 within 30 min of sampling. In addition, other consumables or oral hygiene products that may have 243 persisted in saliva were also included, namely mouthwash, gum/lozenge, tobacco (whether 244 smoked, vaporized, or chewed), and toothpaste from brushing teeth. Many participants had consumed multiple items. In order to make quantitative comparisons between saliva sample Ct 245 values, we report the consumption survey results for individuals who testing positive using 246 247 SalivirDetect (Table 1).

Table 1. Self-reported Demographic Information and Clinical Presentation.		
Characteristic	Participants (N = 233)	
Sex - no.		
Male	109	
Female	124	
Median Age (IQR)* – yr	20 (19-22)†	
Race – no.		
White	220	
Asian	1	
Mixed race	11	
Not provided	1	
Ethnicity – no.		
Hispanic or Latino	9	
Not Hispanic or Latino	207	
Not provided	17	
Clinical Presentation – no.	1	
Symptomatic (known exposure)	76	
Symptomatic (no known exposure)	88	
Asymptomatic (known exposure)	64	
Asymptomatic (no known exposure)	4	
Not provided	1	
Consumption within 30 min of Saliva Sampling ^{††} – no.	1	
Only Food	4	
Only Drink	23	
Both Food and Drink	10	
Neither Food nor Drink	21	
Mouthwash ^{†††}	1	
Yes	5	
No	52	
Gum or Lozengettt		
Yes	6	
No	52	
Tobacco ⁺⁺⁺ (Smoke, Vape, or Chew)		
Yes	7	
No	51	

	Brushed Teeth ^{†††}		
	Yes	31	
	No	27	
249	* Interquartile range.		
250	$^{\dagger}N = 223$ (10 non-respondent).		
251	⁺⁺ Tested positive using SalivirDetect.		
252	tttMultiple selections possible.		

253

254 **Testing outcomes - performance of the three methods**

255 Performance metrics of saliva methods SalivirDetect and SLAMP were evaluated by comparing results to the "gold-standard" CDC-approved NP RT-qPCR method between 233 individuals 256 257 tested using all three methods. We report the true positive (TP), true negative (TN), false positive (FP), and false negative (FN) counts along with the true positive rate (TPR) and true negative rate 258 259 (TNR), also called sensitivity and specificity, respectively (Table 2). The sensitivity/specificity (in 260 %) of SalivirDetect and SLAMP methods were 97/98 and 95/98, respectively. Based on NP RTqPCR, 58 positive and 175 negative individuals were identified resulting in a disease prevalence 261 of 25%. 262

263

Table 2. Test Outcomes and Performance Metrics.				
Method and Category				
NP RT-qPCR (CDC-approved "gold standard")				
Diseased	58			
Non-diseased	175			
Saliva RT-qPCR (SalivirDetect)				
True Positives (TP)	56			
True Negatives (TN)	220			
False Positives (FP)	3			
False Negatives (FN)	2			
Sensitivity (%)	97			
Specificity (%)	98			
Saliva RT-LAMP (SLAMP)				
True Positives (TP)	55			
True Negatives (TN)	172			
False Positives (FP)	3			
False Negatives (FN)	3			
Sensitivity (%)	95			
Specificity (%)	98			

264

265 Comparing positive samples - two sample matrices and three testing methods

The 58 samples found positive under CDC-approved NP RT-qPCR are placed in order of increasing Ct value (decreasing effective SARS-CoV-2 genome concentration or viral titer) and compared to Ct values under SalivirDetect (Figure 2A) and Tp values using SLAMP (Figure 2B). Samples positive under saliva-based tests are compared in order of increasing SalivirDetect Ct value (Figure 2C) and increasing SLAMP Tp value (Figure 2D). False negatives are shown as missing bars and indicated by black arrows.



273 274

275 276

277

278 279

280

281

Figure 2. Positive sample results compared between three tests. Ct values of N=58 positive NP RT-qPCR and SalivirDetect samples in order of increasing CDC-approved NP RT-qPCR Ct value (Panel A). Ct values of N=58 positive CDC-approved NP RT-qPCR and Tp values of SLAMP samples in order of increasing CDC-approved NP RT-qPCR Ct value (Panel B). Ct values of N=59 positive SalivirDetect and Tp values of SLAMP samples presented in order of increasing SalivirDetect Ct value. Dashed line indicates 95% confidence interval SLAMP limit of detection (Panel C). Tp and Ct values of N=58 positive SLAMP and SalivirDetect tests, respectively, in order of increasing SLAMP Tp value (Panel D). Black arrows indicate undetected samples. Error bars represent one standard deviation.

282 283

284 **Test outcomes and viral titers by age**

A total of 223 participants provided age information and among these 56 were confirmed positive for SARS-CoV-2 using CDC-approved NP RT-qPCR. A histogram of these ages shows the positive results (gray) superimposed over the negative results (white), including one outlier age of 63 (Figure 3A). The most common age to be positive and negative is equal to the mode of 19 years old. Not surprisingly, the positive and negative distributions are similar (p = 0.407). Average Ct values as a function of age also indicate no trend in positivity as a function of this narrow age window (Figure 3A, inset).

292

293 Self-reported clinical presentations and test results

294 Participants were classified into four categories defined by their questionnaire responses: symptomatic exposed, symptomatic unexposed, asymptomatic exposed, and asymptomatic 295 296 unexposed. Samples in each self-reported category were confirmed negative or positive based 297 on CDC-approved NP RT-qPCR and positive individuals were assigned a Ct value. The 2nd 298 largest category was symptomatic exposed numbering 76 individuals. Among these, only 20 299 participants were confirmed SARS-CoV-2-positive, around 26%. Symptomatic unexposed, the largest of all four categories, was comprised of 88 individuals from which 27 were confirmed 300 301 positive, around 31%. The asymptomatic and exposed respondents numbered 64, of which only

9 tested positive, a total of only 14%. The smallest category was comprised of four participants
who were asymptomatic and unexposed. Of these, half tested positive. Histograms of Ct values
among the positive results with inset pie charts representing the fraction of confirmed SARS-CoV2 positives (blue) among the negatives (white) for each category are shown in Figure 3B.

306 307 Consumption of potential inhibitors – effect on SalivirDetect Ct values

Distributions of SalivirDetect Ct values among individuals who had or had not consumed each potential inhibitor are shown in Figure 3C. Among those engaging in eating and drinking, only the Ct values of those who drank were statistically distinct compared to those who did not (p = 0.041). No other items consumed resulted in statistically significant differences in the Ct distributions of

- those populations. The p-values for comparisons of all other sets were >0.05.
- 313

314 Site comparison: Nasopharynx versus saliva

CDC-approved NP RT-qPCR and SalivirDetect provide Ct results that can be quantitatively 315 compared between NP swabs and saliva (Figure 3D). We compare the viral titers of 56 individuals 316 who tested positive under both methods. Viral titer has been shown to vary between these sites 317 318 ²⁸. Among samples with lower NP swab Ct values, assumed to correspond to a higher viral titer, 319 saliva samples Ct values were higher, implying a lower viral titer than in the nasopharynx. However, when NP swab Ct values imply lower viral titers, Ct values in saliva were significantly 320 lower, implying a difference in viral concentration between nasopharynx and oral mucosa (saliva) 321 of possibly four orders of magnitude. Furthermore, there is a definite jump in values for the NP 322 323 swab results from Ct=30-34, after which saliva Ct values are all lower than NP swab (Figure 3D, 324 left). A correlation plot of NP vs. saliva Ct values reveals that the results have only a weak positive 325 correlation (r = 0.310).

326

327 Statistical predictions for SLAMP tests at triplicate, duplicate, or as a single replicate

For each number of test replicates, sensitivity increases as a function of SLAMP assay duration 328 329 (Figure 3E). As reported here, 45-min SLAMP with 3 replicates produced a sensitivity of 95% (95% CI: [87.9%, 100%]) as compared to the CDC-approved NP RT-qPCR standard results. 330 Bootstrapping predicted a 90% sensitivity (95% CI: [82.8%, 96.6%]) for SLAMP with two 331 replicates, and a 82% sensitivity (95% CI: [70.7%, 89.7%]) for SLAMP with a single replicate after 332 the full assay time of 45 min had passed. For example, half of all positives in a test population 333 334 would be detected by a single SLAMP test after 19.0 min (95% CI: [17.7 min, 21.5 min]), duplicate 335 tests after 18.4 min (95% CI: [17.4 min, 19.3 min]), and triplicate tests after 17.7 min (95% CI: 336 [16.9 min, 18.8 min]).

337

Based upon an estimated testing capacity of six 384-well plates per day (see Methods), we 338 339 compare three scenarios of running samples with a single replicate, duplicate, and triplicate 340 (Figure 3F). For these scenarios, we use the sensitivity values from Figure 3E. The specificity is assumed to be a constant 98% for all scenarios and there are 10 wells in each plate reserved for 341 controls. Given the fixed constraint on the number of tests ($\approx 384 \times 6$), screening a larger number 342 of individuals can identify more positive cases. For example, at a disease prevalence of 10%, 343 triplicate SLAMP would identify approximately 10.0 true positives (TP) at the cost of 2.4 false 344 positives (FP) per 384-well plate with FPs equaling the number of TPs at a disease prevalence of 345 2.5%. For duplicate SLAMP, TP = 16.8, FP = 3.3, and TP = FP at a disease prevalence of 2.2%. 346 347 Finally, for single test SLAMP, TP = 35.4, FP = 6.9, and TP = FP at a disease prevalence of and 348 2.0%.

- 349
- 350



Figure 3. Study results and statistical predictions. Histogram of participant age distributions, N=223. Gray and white bars represent positive and negative participants, respectively, tested using CDC-approved NP RT-qPCR (p = 0.407). Inset: average Ct values of SARS-CoV-2-positive CDC-approved NP RT-qPCR tests as a function of participant age (r = 0.00539). Error bars represent one standard deviation (Panel A). Histograms of CDC-approved NP RT-qPCR Ct

358 values of SARS-CoV-2-positive participants self-reported as (from left-to-right) symptomatic 359 exposed (N=76), symptomatic unexposed (N=88), asymptomatic exposed (N=64), and 360 asymptomatic unexposed (N=4). Insets: fraction of positive tests (blue) and negative tests (white) 361 within each category (Panel B). Box-and-whisker plots of SalivirDetect Ct values for individuals who both ate and drank (N=10), ate only (N=4), drank only (N=23), and did neither (N=21) (left 362 panel) in addition to having used mouthwash (N=5), no mouthwash (N=52), gum/lozenge (N=6), 363 no gum/lozenge (N=52), tobacco (N=7), no tobacco (N=51), brushing (N=31), and no brushing 364 (N=27) (right panel) within 30 min of saliva sampling. Box-and-whisker plots define minimum, first 365 366 quartile, median, third quartile, and maximum values (Panel C). Comparison between collection sites on the body. The Ct values of 56 positive CDC-approved NP RT-qPCR samples are plotted 367 in increasing order (closed black squares). Open blue circles represent the SalivirDetect Ct values 368 369 of the 56 corresponding saliva samples. Vertical lines connect NP and saliva values to guide the 370 eye (left subplot). Cluster plot of Ct values of CDC-approved NP RT-qPCR vs. SalivirDetect. Dashed line indicates perfect correlation (r = 0.310) (right subplot) (Panel D). Bootstrap-predicted 371 percentage of total positive individuals detected within a testing population as a function of 372 SLAMP assay time for triplicate, duplicate or single replicate test conditions. Dashed lines indicate 373 the mean. Solid lines indicate 95% bootstrap confidence intervals (Panel E). Total number of 374 375 positive cases identified using SLAMP per 384-well plate as a function of disease prevalence for three, two, and single replicate tests. True positives (blue) and false positives (red) are generated 376 377 for disease prevalence rates between 0 and 10% for single replicates, duplicates, and triplicates based on a daily capacity of six 384-well plates, reserving 10 wells for controls (Panel F). 378

379380 Safety

Testing site volunteers were equipped with powered air-purifying respirators (PAPRs) during sample collection. Samples were transported in hard-sided coolers with biohazard labels. Contact surfaces were frequently disinfected using 70% ethanol solutions. All samples should be assumed to contain infectious SARS-CoV-2 virus and must be rendered safe through viral inactivation²⁹ before testing. HEPA air purifiers (Medify Air MA-25) were used in the testing laboratory. All samples were heat inactivated before storage. See Supplementary Methods and Figure S4 for validation of viral heat-inactivation procedure.

388389 **Discussion**

390

The demographics of this study (Table 1) reflect those of many universities throughout the US. 391 The median age of study participants was 20 years, and 94% of participants were ages 18-24. 392 This study was comprised of 53% females and 47% males. By comparison, the 2020 MSU student 393 394 population was comprised of 48% females, 51% males, and <1% other³⁰. This difference is in agreement with observations that suggest women seek Covid-19 testing, more than males^{31,32} 395 and are more likely to take covid precautions seriously³³. In terms of race, this study was 396 comprised of 94.4% white and 5.6% non-white participants. By comparison, the 2020 MSU 397 student population was comprised of 84% white and 16% non-white³⁰. This difference of 10% 398 may reflect differences in likelihood to seek Covid-19 testing³⁴. The average US university in Fall 399 2020 was around 49% white³⁵, more racially diverse than represented within our study. 400 Nevertheless, we have no reason to doubt that SLAMP testing would be successfully employed 401 402 among the student populations of other universities.

403

404 RT-LAMP (SLAMP) and RT-qPCR (SalivirDetect) Covid-19 tests performed on the saliva of 233
 405 adults³⁶ yielded 98% specificity for both and 95% and 97% sensitivity, respectively, sensitivities
 406 comparable to SalivaDirect³⁷.

408 Surveying revealed that while 70% of pilot study participants identified as symptomatic, only 29% of these tested positive for SARS-CoV-2 (Table 2). Overall, the prevalence of Covid-19 disease 409 410 was 25%, a number that coincides with incidence levels of 9-31% across the US, as estimated in the months prior to our study³⁸. Only 5% were asymptomatic positives compared to the estimates 411 of around 40% asymptomatic among the general population³⁹ which is likely due to testing being 412 reserved only for those with symptoms or recent exposures. We expect a random screening of 413 the population would likely have produced a higher asymptomatic positive rate, given estimates 414 ranging from 40-45% asymptomatic positive rate⁴⁰. 415

416

While interference from food, drink, oral care products, and tobacco are a concern for saliva diagnostics⁴¹, we observed no significant differences in Ct distributions of SalivirDetect positive results who had or had not consumed food, oral care products, or tobacco within 30 min of saliva sampling. Interestingly, those who had consumed drink produced significantly lower Ct values (p = 0.407) than those who had not (Figure 3C). This suggests that hydrating the mouth before expressing saliva may stimulate its production, at least temporarily⁴², and contribute to the supply of greater viral genome from the oral mucosa⁴³.

424

Viral load in saliva is consistently higher than NP swab. Strikingly, positive samples with the highest CDC NP RT-qPCR Ct values >30 are surprisingly lower than in saliva, representing a higher concentration of virus in the saliva of the oral mucosa under conditions of low titer in the nasopharynx (Figure 3D). In fact, all saliva samples had Ct \leq 35, and the 9 individuals with the lowest NP swab virus concentrations (Ct > 35) had significantly lower Ct for the corresponding saliva sample test. SARS-CoV-2 infections have exhibited high tissue compartmentalization and data suggests viral titers may peak earlier in saliva than in NP swabs²⁴.

432

433 While the SLAMP test has higher sensitivity when run in triplicate, running a single test can be advantageous. Given finite resources, driven by cost or supply availability, a single test on an 434 435 individual can identify a substantially larger amount of infected, and infectious, individuals. We 436 modeled the sensitivities and specificities of double and single tests from the triplicate SLAMP 437 test data. Figure 3F shows the total number of positive individuals that can be identified by running a single 384-well plate in either triplicate, duplicate, or with a single test. Triplicate and duplicate 438 have higher sensitivity, with 95% and 90% respectively, compared to that of a single test at 82%; 439 440 however, running a single test allows more individuals to be tested.

441

442 It should be noted that specificity is assumed constant across the three SLAMP replicates (Figure 3F, red lines). Therefore, running more tests, with a lower specificity can also lead to more false 443 positives that may require confirmatory testing. Recent work¹⁰ has demonstrated that more 444 445 frequent testing with LAMP was more effective at reducing epidemic size than deploying more 446 sensitive tests. Our analyses regarding sensitivity predict that running more samples with single replicates will lead to more false negatives, but ideally a high frequency testing strategy would 447 catch those other cases¹⁰. Nonetheless, the data suggest that the SLAMP assay run in triplicate 448 per individual could perform at the level of a clinical diagnostic, while when run as a single 449 450 replicate could be used as a broad screening tool to identify unknown positives.

451

These results represent the intersection of self-reported demographics, disease presentation, and potential interferences. Our study size of N=233 with 58 diseased can be statistically interpreted with acceptable accuracy¹⁰. However, the sample number in the case of some interferences is low and limits statistical power.

456

457 SARS-CoV-2 testing that is rapid, simple, and requires no specially trained medical personnel is 458 indispensable when large numbers of individuals must be frequently screened while remaining

459 economical. In this study, we have compared three testing methods, NP RT-gPCR, SalivirDirect. and SLAMP. All three methods use simple heat to both inactivate and extract, which avoids costly 460 461 reagents and potential supply bottlenecks. We conducted a comparison of these tests between 233 individuals from the MSU symptomatic testing site in mid-November of 2020, at the height of 462 the largest county-wide wave of Covid-19 cases, where we detected a disease prevalence of 463 25%. Compared to the "gold standard" NP RT-gPCR results, SalivirDetect and SLAMP achieved 464 97% and 95% sensitivity and 98% and 98% specificity, respectively. We have demonstrated our 465 SLAMP method offers a faster and simpler, while still comparatively sensitive, alternative to NP 466 467 swabs and RT-qPCR methods for routine sampling, particularly of a college population.

- 468
- 469 470
- 471 Supported by the State of Montana through the Coronavirus Aid, Relief and Economic Security 472 Act (CARES) Act.
- 473

474 Connie B. Chang and James N. Wilking are co-founders of ULTSafety, Inc. which has licensed
 475 technology from Montana State University and Harvard University relating to this publication.
 476

We thank Nathan Tanner at New England Biolabs, Kathryn Kundrod in the Richards-Kortum 477 478 group (Rice University), Paul Hergenrother (UIUC), and the Global LAMP R&D Consortium led 479 by Christopher Mason (Weill Cornell Medicine) for helpful discussions. We thank MSU students 480 Kyle Hain, Shawna Pratt, Emily Walter, Matthew Fisher, and Jerrica Bursik for sample collection 481 and Donna Gollehon (MSU University Health Partners), Ryan Brickman (MSU Safety and Risk Management), and Ryan Bartlett (MSU Office of Research Compliance) for their assistance 482 483 throughout the approval process and especially with sample site logistics. We thank the MSU 484 Center for American Indian and Rural Health Equity for the use of the Health Education and 485 Research Bus (HERB) at the sample collection site. HERB is a mobile laboratory and outreach 486 facility supported by an Institutional Development Award (IDeA) from the National Institute of 487 Medical Sciences of the National General Institutes of Health under arant numbers P20GM104417 and P20GM103474. 488

489

490 Author Affiliations

491

From the Montana State University Department of Chemical & Biological Engineering (D.A.B.,
E.K.L., T.L., I.T., J.N.W., C.B.C.), Center for Biofilm Engineering (D.A.B., C.H., K.A.B., A.P.,
E.K.L., T.L., I.T., J.N.W., J.M., M.W.F., C.B.C.), Department of Microbiology & Immunology (M.R.,
S.T.W., R.K.B., M.P.T., D.E.K., M.W.F.), Department of Mathematical Sciences (A.P., A.B.H.),
Center for American Indian and Rural Health Equity (CAIRHE) (A.K.A.), and Health & Human
Development (J.R.C.).

498

Address reprint requests to co-corresponding authors Connie B. Chang, Ph.D. or Matthew W. Fields, Ph.D. at the Department of Chemical and Biological Engineering or Department of Microbiology and Immunology, respectively, Center for Biofilm Engineering, Montana State University, 366 Barnard Hall, Bozeman, MT 59717, or at connie.chang@montana.edu or matthew.fields@montana.edu, respectively.

- 504
- 505
- 506
- 507
- 508
- 509

510 **<u>References</u>**

511

5121.Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging513in China — Key Questions for Impact Assessment. New England Journal of Medicine 2020;382:692-4.

Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not)
 in the room. Lancet Microbe 2021.

516 3. Thompson RN, Hill EM, Gog JR. SARS-CoV-2 incidence and vaccine escape. Lancet Infect Dis 2021.

517 4. Castillo JC, Ahuja A, Athey S, et al. Market design to accelerate COVID-19 vaccine supply. Science 518 2021;371:1107-9.

5. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and 520 duration of immunity: a longitudinal study. Lancet Microbe 2021.

521 6. Kirby T. When should the UK lift its lockdown? Lancet Respir Med 2021;9:e44-e5.

522 7. Head JR, Andrejko KL, Cheng Q, et al. School closures reduced social mixing of children during 523 COVID-19 with implications for transmission risk and school reopening policies. J R Soc Interface 524 2021;18:20200970.

525 8. Guidance for Antigen Testing for SARS-CoV-2 for Healthcare Providers Testing Individuals in the 526 Community. (Accessed Updated Apr. 4, 2022, at <u>https://www.cdc.gov/coronavirus/2019-</u> 527 <u>ncov/lab/resources/antigen-tests-guidelines.html</u>.)

528 9. Mina MJ, Andersen KG. COVID-19 testing: One size does not fit all. 2021;371:126-7.

10. Rogers W, Ruiz-Aravena M, Hansen D, et al. High-frequency screening combined with diagnostic
testing for control of SARS-CoV-2 in high-density settings: an economic evaluation of resources allocation
for public health benefit. 2021:2021.03.04.21252949.

53211.Mori Y, Notomi T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-533effective diagnostic method for infectious diseases. J Infect Chemother 2009;15:62-9.

53412.Bhadra S, Maranhao AC, Paik I, Ellington AD. A One-enzyme RT-qPCR Assay for SARS-CoV-2, and535Procedures for Reagent Production. Bio-protocol 2021;11:e3898.

53613.Buck MD, Poirier EZ, Cardoso A, et al. Standard operating procedures for SARS-CoV-2 detection537by a clinical diagnostic RT-LAMP assay. medRxiv 2020:2020.06.29.20142430.

538 14. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to
539 widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA (New
540 York, NY) 2020;26:771-83.

54115.Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid542diagnostic for COVID-19. Medical Hypotheses 2020;141:109786.

Yan C, Cui J, Huang L, et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by
a reverse transcription loop-mediated isothermal amplification assay. Clin Microbiol Infect 2020;26:7739.

54617.Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/Severe547Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated548isothermal amplification. PLoS One 2020;15:e0234682.

54918.Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-CoV-5502 detection. The Lancet Respiratory Medicine.

551 19. For Coronavirus Testing, the Nose May Not Always Be Best. The New York Times Jan. 14, 2022.

552 20. Thompson D, Lei Y. Mini review: Recent progress in RT-LAMP enabled COVID-19 detection. 553 Sensors and actuators reports 2020;2:100017-.

https://sc.edu/study/colleges schools/pharmacy/centers/diagnostic genomics covid lab/salivir-

554 21. SalivirDetect.

2021,

at

556 <u>detect/index.php</u>.)

557 22. A new process that can be used in place of the extraction method when materials for the current 558 method are limited. at <u>https://www.fda.gov/media/138931/download</u>.)

559 23. Diseases CDNDoV. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
560 In: Prevention CfDCa, ed. CDC-006-00019, Revision: 06 ed12/01/2020.

561 24. Ke R, Martinez PP, Smith RL, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals 562 substantial heterogeneity in infectiousness. Nature Microbiology 2022;7:640-52.

563 25. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall; 1993.

56426.Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect5652020;81:e48-e50.

566 27. Corstjens PLAM, Abrams WR, Malamud D. Saliva and viral infections. Periodontol 2000 567 2016;70:93-110.

568 28. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for 569 detection of SARS-CoV-2. N Engl J Med 2020;383:1283-6.

Adaway JE, Hawley JM, Lockhart SJ, Keevil BG. Heat Inactivation of Saliva Samples for the Analysis
of Cortisol and Cortisone during the COVID-19 Pandemic. The Journal of Applied Laboratory Medicine
2020;5:1413-6.

573 30. Quick Facts: 2020-2021. Montana State University, 2020-2021. 2021, at 574 <u>https://www.montana.edu/opa/facts/quickfactsarchive/quick21.html</u>.)

575 31. Lapointe-Shaw L, Rader B, Astley CM, et al. Web and phone-based COVID-19 syndromic 576 surveillance in Canada: A cross-sectional study. PLOS ONE 2020;15:e0239886.

577 32. Stall NM, Wu W, Lapointe-Shaw L, et al. Sex- and Age-Specific Differences in COVID-19 Testing, 578 Cases, and Outcomes: A Population-Wide Study in Ontario, Canada. 2020;68:2188-91.

57933.Galasso V, Pons V, Profeta P, Becher M, Brouard S, Foucault M. Gender differences in COVID-19580attitudes and behavior: Panel evidence from eight countries. 2020;117:27285-91.

Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS-CoV-2
 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. American journal of preventive
 medicine 2021;61:644-51.

584 35. Fast Facts. 2020. at <u>https://nces.ed.gov/fastfacts/display.asp?id=372</u>.)

58536.Bujang MA, Adnan TH. Requirements for Minimum Sample Size for Sensitivity and Specificity586Analysis. J Clin Diagn Res 2016;10:YE01-YE6.

587 37. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to 588 enhance SARS-CoV-2 testing capacity. Med 2021;2:263-80.e6.

38. Reese H, Iuliano AD, Patel NN, et al. Estimated Incidence of Coronavirus Disease 2019 (COVID-19)
Illness and Hospitalization—United States, February–September 2020. Clinical Infectious Diseases
2020;72:e1010-e7.

59239.Ma Q, Liu J, Liu Q, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the593Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-594analysis. JAMA Network Open 2021;4:e2137257-e.

59540.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection A Narrative Review. Ann596Intern Med 2020;173:362-+.

597 41. Kapoor P, Chowdhry A, Kharbanda OP, Popli DB, Gautam K, Saini V. Exploring salivary diagnostics
598 in COVID-19: a scoping review and research suggestions. Bdj Open 2021;7.

Jose A, Singh ML, Magnuson B, Farag A, Varghese R, Papas A. A randomized controlled study to
evaluate an experimental moisturizing mouthwash formulation in participants experiencing dry mouth
symptoms. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2018;126:231-9.e5.

43. Benn AM, Thomson WM. Saliva: an overview. The New Zealand dental journal 2014;110:92-6.